Filing summary
Entity and period: The supplied filing is Synta Pharmaceuticals Corp.’s unaudited Form 10-Q for the quarter ended September 30, 2011—not a filing by Madrigal Pharmaceuticals, Inc. Investors should verify the company and filing identity before relying on this summary. Amounts below are in U.S. dollars; financial statement figures are in millions unless noted.
Business context and financial results
Synta was a clinical-stage biopharmaceutical company developing oncology and inflammatory-disease drug candidates. It reported no product sales and relied on collaboration revenue, grants, equity financing and debt. Its principal clinical-stage programs were ganetespib and elesclomol; STA-9584 and inflammatory-disease programs were earlier-stage.
| Metric | Q3 2011 | Q3 2010 | Nine months 2011 | Nine months 2010 |
|---|---|---|---|---|
| Revenue | $1.664 | $3.383 | $4.161 | $10.766 |
| Research and development expense | $10.751 | $11.023 | $30.605 | $30.906 |
| General and administrative expense | $3.131 | $2.591 | $8.749 | $8.393 |
| Operating loss | $(12.218) | $(10.231) | $(35.193) | $(28.533) |
| Net loss | $(12.734) | $(10.262) | $(36.637) | $(28.644) |
| Net loss per share | $(0.30) | $(0.25) | $(0.87) | $(0.71) |
The filing does not present gross profit or gross margins. Operating and net losses widened year over year despite lower R&D expense, principally reflecting reduced Roche cost-sharing revenue and higher interest expense. Nine-month revenue fell 62%; Roche cost-sharing revenue ceased after its initial research term ended in 2010. License revenue from Roche was $3.429 million for the first nine months of both years. Grant revenue was $0.732 million in 2011, including $0.521 million in Q3.
Cash, liquidity and debt
- At September 30, 2011, cash and cash equivalents were $20.643 million and marketable securities were $30.017 million, totaling $50.660 million. Total current assets were $52.022 million; working capital was reported as $34.9 million.
- For the first nine months, operating cash use was $36.814 million; investing cash use was $10.658 million; financing provided $36.805 million. Cash and cash equivalents declined $10.667 million from year-end 2010.
- Term-loan principal was approximately $16.767 million. GECC debt carried 9.75% interest, with interest-only payments through January 2012 and scheduled principal payments thereafter; Oxford debt carried 13.35% interest. The GECC loan is secured by substantially all assets other than intellectual property, with a contingent IP security interest under specified covenant circumstances.
- April 2011’s registered direct offering raised approximately $34.8 million net through issuance of 7,191,731 shares. The Azimuth equity facility allowed sales up to $35 million or 8,106,329 shares, subject to conditions; no shares had been sold under it as of the filing.
Developments, outlook and risks
- Management estimated existing cash resources would fund operations into the second half of 2012, based on then-current operating levels and assumptions about available resources. It said spending could increase as trials advance and additional studies begin, and additional funding could be needed earlier than expected.
- The GALAXY Phase 2b/3 program of ganetespib plus docetaxel versus docetaxel alone in non-small cell lung cancer began in Q2 2011. Interim Phase 2b data were expected in early 2012; management anticipated possible additional ganetespib trials in 2012. These are forward-looking statements, not assured outcomes.
- Management reported encouraging but early clinical signals for ganetespib, including a 54% disease control rate in a Phase 2 NSCLC trial and responses among small biomarker-defined groups. Results require further clinical confirmation. Elesclomol was being studied in ovarian cancer and acute myeloid leukemia; management planned a Phase 2b NSCLC trial in 2012. STA-9584 development was supported by an approximately $1 million Department of Defense grant.
- Roche could owe substantial development and commercialization milestones and tiered royalties if specified conditions are met; no development milestones had been achieved by September 30, 2011. Synta did not expect further Roche research-cost reimbursements.
- Key risks include clinical failure or delay, regulatory uncertainty, continuing operating losses, dependence on external financing and partnerships, possible dilution or unfavorable licensing terms, and the uncertainty of achieving product revenue. The company reported no material legal proceedings, no material change to its previously disclosed risk factors, and effective disclosure controls.
Important facts to verify
- Confirm the filing belongs to Synta Pharmaceuticals Corp.; the request names Madrigal Pharmaceuticals, Inc.
- Confirm the reported cash runway assumptions and the timing and cost of planned trials, especially GALAXY and any 2012 studies.
- Review loan terms, security interests, scheduled principal payments and the availability and dilution implications of the Azimuth facility or other financing.
- Check subsequent clinical-trial results and whether anticipated Roche milestones, royalties or new partnerships materialized.